These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 17280499

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ.
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Alemtuzumab: what is the secret to safe therapy?
    Elter T, Hallek M, Montillo M.
    Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
    [Abstract] [Full Text] [Related]

  • 5. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
    Rai KR.
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S15-22. PubMed ID: 16720199
    [Abstract] [Full Text] [Related]

  • 6. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T.
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [Abstract] [Full Text] [Related]

  • 7. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H, German Chronic Lymphocytic Leukemia Study Group.
    J Clin Oncol; 2009 Aug 20; 27(24):3994-4001. PubMed ID: 19597025
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G, Slavin S, Goldman JM, Mackinnon S, Giralt S, Waldmann H.
    Bone Marrow Transplant; 2002 Dec 20; 30(12):797-804. PubMed ID: 12476271
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F.
    Nucl Med Biol; 2008 Jul 20; 35(5):599-604. PubMed ID: 18589304
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.